who we are
Rxilient offers full value chain capabilities, from registration and commercialization to manufacturing and supply chain management. Partnering with innovators and multinationals to develop and commercialize leading medicines.
Mission
We transform lives through connecting global innovation to local patients.
Vision
Become the leading pharma company in emerging markets, recognised for offering high-quality, accessible and affordable therapies to patients.
Customer Value Proposition
With its unique local presence and expertise, Rxilient facilitates the development, registration, supply and commercialization of global innovative products in complex emerging markets.
Core Values
- Customer Focus
- Innovation
- Pragmatic
- Integrity
- Resilience
- Win-win
our history
The journey of Rxilient began in 2021 with the establishment of three entities in Singapore, committed to healthcare innovation and market alignment.
-
2021
Inception of Rxilient Singapore.
-
2022
Rxilient’s geographic expansion included the setup of operations in Shanghai, Malaysia, and Indonesia.
-
2023
- Continued global reach with new offices in the Philippines, Thailand, and Vietnam.
- Strategic launch of Excellmab, a joint venture between Rxilient Biotech and Junshi Biosciences, to develop and commercialize Toripalimab in Southeast Asia.
-
2024
Rxilient’s expansion into Taiwan and Dubai through new office establishments.
